To investigate the in¯uence of the pancreas lipase inhibitor orlistat (OLS) on calcium metabolism, bone turnover, bone mass, bone density and body composition when given for obesity as adjuvant to an energy-and fat-restricted diet. DESIGN: Randomized controlled double-blinded trial of treatment with OLS 120 mg three times daily or placebo for 1 y. SUBJECTS: Thirty obese subjects with a mean body mass index (BMI) of 36.9 AE 3.7 kgam 2 and a mean age of 41 AE 11 y. Sixteen patients were assigned to OLS and 14 to placebo. MEASUREMENTS: Dual energy X-ray absorptiometry (DXA) measurements of bone mineral and body composition included total bone mineral content (TBMC), total bone mineral density (TBMD), lumbar spine BMC and BMD, forearm BMC and BMD, fat mass (FM), fat free-mass (FFM), percentage fat mass (FM%) as well as a DXA estimate of the body weight. Body composition (FM, FFM and FM%) was estimated by total body potassium (TBK). Indices of calcium metabolism and bone turnover included serum values of ionized calcium (Ca ), iPTH (parathyroid hormone), alkaline phosphatase, 25(OH)-vitamin D, 1,25(OH) 2 vitamin D and osteocalcin as well as fasting urinary ratios of hydroxyprolineacreatinine and Caacreatinine (fU-OHpracreat, fUCaacreat). RESULTS: There were no signi®cant differences between OLS and placebo groups as to any of the body composition variables (FFM, FM, FM%) at baseline or after 1 y treatment. Weight loss was of 11.2 AE 7.5 kg in the OLS group and 8.1 AE 7.5 kg in the placebo group (NS). The changes in FM and FM% were signi®cant in both groups determined by DXA as well as by TBK, but the group differences between these changes were not signi®cant. The composition of the weight loss was approximately 80% fat in both groups. FFM only changed signi®cantly by DXA in the OLS group (71.3 kg), but the difference from the placebo group was not signi®cant. Forearm BMD in both groups, forearm BMC in the OLS group and TBMD in the placebo group fell discretely but signi®cantly, but there were no signi®cant group differences between the OLS and the placebo-treated group. All biochemical variables except s-osteocalcin changed signi®cantly after 1 y in the OLS group, disclosing a pattern of an incipient negative vitamin D balance, a secondary increase in PTH-secretion, and an increase in bone turnover with the emphasis on an increase in resorption parameters (fU-OHpracreat, fUCaacreat). In the placebo group, only s-25(OH)vitamin D and fUOHpracreat changed signi®cantly, but the pattern was also that of a deteriorated vitamin D status and an increase in PTH levels and bone turnover. The only biochemical variable which was signi®cantly different between OLS and placebo groups after one year was the fU-OHpracreat ratio, which increased from 12.0 to 20.1 in the OLS group but only from 10.9 to 13.2 in the placebo group. CONCLUSION: One year's treatment with OLS induces a lipid malabsorption which enhances a dietary weight loss without any signi®cant deleterious effects on body composition. OLS induces a relative increase in bone turnover in favour of resorption, possibly due to malabsorption of vitamin D andaor calcium. However, no changes in bone mass or density are seen after 1 y of OLS treatment apart from those explained by the weight loss itself. Thus 1 y of OLS treatment seems safe from a`bone preserving' point of view. A vitamin D and calcium supplement should be taken during the treatment.
Introduction
Orlistat (OLS) is a recently introduced pharmacological treatment of obesity. 1 It promotes weight loss by reducing fat uptake from the intestine through a partial pancreas lipase inactivation which causes a 30% malabsorption of dietary fat.
Obesity in¯uences calcium metabolism and bone status. Obese subjects most frequently have increased bone mass and bone density, 2 ± 7 which is known to fall towards the level of non-obese subjects after weight loss. 3, 4, 8, 9 The pathophysiological mechanism for this is not known but may be related to some humoral mediator, eg changes in parathyroid function. 10 ± 12 Morbid obesity was in one study associated with secondary hyperparathyroidism, which normalized with dietary weight loss. 13 Also the excess amount of fat tissue may stimulate bone formation through the mechanical load on the skeleton.
It is known from various clinical conditions that fat malabsorption can be associated with a signi®cant intestinal loss of dietary calcium and vitamin D which may lead to osteomalacia. Fat malabsorption as a treatment for obesity was ®rst introduced through jejunoileal bypass operations, and bypass patients were reported to be at risk of vitamin D hypovitaminosis, hypocalcemia, secondary hyperparathyroidism and osteomalacia. 3,14 ± 16 Fat malabsorption induced by OLS is gererally more limited than that induced by jejunoileal bypass surgery. As OLS in other aspects may prove safe for long-term use, it is of interest to investigate possible changes in calcium metabolism and bone mineral content during long-term treatment of obesity with OLS.
Treating obesity, the aim is to reduce fat mass selectively and to spare not only bone tissue but lean body mass as a whole. Thus, the composition of the weight lost is crucial and therefore it is of interest to determine changes in body composition in relation to new weight loss regimens and drugs.
On this background the present study compared calcium metabolic variables, bone mineral content and composition of the body mass lost during 1 y of treatment of obesity with either OLS or placebo as supplement to the recommended energy and fat restricted diet.
Patients
Patients included in the present study represented a subsample of the patients resently reported on by Sjo Èstro Èm et al.
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Criteria for entry were age b 18 y, body mass index (BMI) between 30 and 43 kgam 2 , and a motivation for weight loss. All the subjects had been obese for several years, but were otherwise healthy as assessed from history, physical examination, routine blood tests, abdominal ultrasound examination and ECG. None were taking any medication known to in¯uence fat-free mass, fat mass or calcium metabolism. Women with a childbearing potential were included if they were using adequate non-hormonal contraception.
The Copenhagen center included a total of 48 patients in the main protocol. The present analysis comprises all patients (n 30, age 41 AE 11 y, BMI 36.9 AE 3.7 kgam 2 ) who completed the ®rst year of the study. All patients were given a hypocaloric diet (600 kcaladay de®cit) with 30% of the energy from fat. Sixteen patients were randomized to treatment with OLS 120 mg three times daily and 14 patients had placebo. Clinical data are shown in Table 1 . Initially there were no signi®cant differences between the OLS and placebo groups regarding age, height, weight and BMI. There was a non-signi®cant tendency towards a greater height and weight in the OLS group, partly due to the overrepresentation of men (three in the OLS group, one in the placebo group). The different number of subjects in the two groups (16 in the OLS group, 14 in the placebo group) is due to the fact that this study is a substudy of a larger multicenter randomized controlled trial.
Methods
Bone mineral content (BMC) and density (BMD) were measured by dual energy X-ray absortiometry (DXA) using a Norland XR36 densiometer. BMC and BMD were measured in the total body (TBMC and TMBD) as well as in the distal forearm (BMC fa and BMD fa ) and in the lumbar spine (BMC ls and BMD ls ). 17 ± 19 Body composition was measured by two methods: (1) dual energy X-ray absorptiometry (DXA) using the above-mentioned Norland XR36 densitometer. This apparatus determines body weight, fat-free mass (FFM) (which includes the bone mineral content), and fat mass (FM). 17 ± 20 (2) Measurement of total body potassium (TBK) by counting the naturally occurring 40 K in a whole body counter. 20, 21 TBK has a constant ratio to the FFM.
Body weight was measured to the nearest 0.1 kg using a precision hospital scales. The precision (CV%) for the DXA BMC and BMD measurements was 1 ± 2%, and the accuracy (SEE%) 3 ± 6%. 17, 19, 20 The precision (CV%) for DXA FFM, FM and FM% was 2 ± 3%, and the accuracy (SEE%) was 4 ± 15%. 18 ± 20 The precision (CV%) from the TBK measurement was 2.7% for FFM, 5.0% for FM, and 1.73% for FM%. 20 All DXA measurements were performed before drug treatment and after 1 y of treatment, ie 1 month after run-in and after 11 months treatment with either OLS or placebo. Specimens for the biochemical analyses were obtained with the same interval.
Bone metabolism was evaluated from serum measurements of ionized calcium, total alkaline phosphatase and iPTH, as well as 1,25(OH) 2 D 3 by RIA (CV 14%), 22 25(OH)D 2 D 3 by competitive proteine binding (CBP) (CV 10%), 23 osteocalcin ( BGP) by RIA (CV 6.5%), 23 fasting urinary hydroxyprolineacreatinine ratio 24, 26 and fasting urinary calciumacreatinine ratio. 26, 27 All specimens were Orlistat, bones and body composition A Gotfredsen et al kept frozen at 718 C until analysis, which was performed blinded with specimens in random order.
Statistics
Data were calculated as mean values and their con®dence intervals (CI). Differences between treatment groups were evaluated by the Student's t-test for unpaired data. Differences within treatment groups between start and end of the study were evaluated by the Student's t-test for paired data. Relationships between variables and between changes in variables were evaluated by standard linear correlation and regression analysis. The level for statistical signi®cance was P`0.05.
Ethics
Before entering the study all participants were informed about the nature and the purpose of the study and all gave their informed consent. The study protocol was approved by the Ethical Committee for Copenhagen and it complied with Helsinki Declaration II of 1975 as revised in 1983. The patient data ®le was approved by the Danish Data Protection Agency. Table 2 shows the results of the body composition analysis by TBK and DXA at the beginning and at the end of the study for the two groups (OLS and placebo). Body weights given together with the TBK values are those obtained with hospital scales. Body weights given together with the DXA values are those obtained with the DXA machine itself. There were no signi®cant group differences regarding any of the variables, either before or after the study. There were tendencies towards small differences between the weights by DXA and by scales (from 1.1 to 1.4 kg) which were, however, not statistically signi®cantly different. Table 3 shows the changes in body composition variables by TBK and DXA in the two groups. Both groups experienced a signi®cant weight loss, which was, however, not signi®cantly different between the groups. There was a non-signi®cant trend towards a more pronounced weight loss with OLS than with placebo treatment: OLS group 12.9 kg (DXA) and 11.2 kg (hospital scales); placebo group 10.0 kg (DXA) and 8.1 kg (hospital scales). The FM and the FM% fell signi®cantly in both groups, but not signi®cantly differently so between the groups. Changes in FFM were very small and only signi®cant with DXA in the OLS-group (1.3 kg). This change was, however, not signi®-cantly different from that of the placebo group. With TBK, FFM fell insigni®cantly in the OLS group (1.3 kg) and rose insigni®cantly in the placebo group, giving rise to a signi®-cant group difference.
Results
Bone mineral content and density measurements did not change signi®cantly except for the forearm measurements (Table 4 ). All changes were, however, very small (including those of the forearm), and no signi®cant group differences were seen for any of the bone measurements.
The biochemical variables (Table 5) showed several signi®cant changes, probably due to dieting and weight loss. S-iPTH increased moderately but signi®cantly in both groups (no signi®cant group difference). S-25-OH vitamin D in both groups and 1,25(OH) 2 vitamin D in the OLS group fell signi®cantly (no signi®cant group difference). S-alkaline phosphatase, a marker of bone formation, increased moderately and signi®cantly so in the OLS group (no signi®cant group difference). S-osteocalcin, also a marker of bone formation, did not change signi®cantly, either within or between the groups.
The only variable that changed signi®cantly different in the OLS and the placebo group was the fasting urinary hydroxyprolineacreatinine ratio (fU-OHpracreat), a marker of bone resorption. It rose signi®cantly in both groups, and signi®cantly more so in the OLS group (Table 5 and Fig. 1 ). Fasting urinary calciumacreatinine ratio, another marker of bone resorption, rose signi®cantly in the OLS group, but not signi®cantly in the placebo group (no signi®cant group difference).
Linear regression analysis showed no relationships between the changes in any of the bone mineral variables and changes in any of the biochemical variables.
Discussion
The lack of signi®cant differences between OLS and placebotreated patients in all bone mineral measurements and in most biochemical variables during 1 y of approximately 10 kg weight loss shows that, at least with this duration of treatment, OLS is a safe drug in terms of preserving bone mineral content and density and maintaining calcium homeostasis. Partly due to the weight loss and partly due Orlistat, bones and body composition A Gotfredsen et al Orlistat, bones and body composition A Gotfredsen et al to the malabsorption induced by OLS, signi®cant changes and group differences in more of the reported variables could be expected. There were some modest changes. The BMC and BMD values of the forearm declined signi®cantly (but not signi®cantly differently between the groups), and the fasting urinary hydroxyprolineacreatinine ratio (marker of bone resorption) rose signi®cantly more in the OLS treatment group than in the placebo group. Several of the other biochemical variables also changed, demonstrating a state indicative of increased malabsorption of vitamin D and calcium, increased bone turnover, increased bone resorption and a tendency towards a secondary hyperparathyroidism. As mentioned earlier, these changes were, however, not signi®cantly different between OLS and placebo. Thus, treatment with OLS seems to induce a moderate malabsorption, with a resulting limited in¯uence on calcium metabolism. However, during 1 y of treatment, no effect was seen on bone mass or density other than the decline expected from weight loss per se.
In spite of more than 20 y of effort to investigate the matter, the question of the in¯uence of obesity and weight loss on BMC and BMD is still controversial. Several studies have found a signi®cant positive relationship between BMC or BMD in most anatomical sites and total body weight, lean body mass and fat mass.
5 ± 7,28 ± 32 Generally, obese subjects have 2 ± 20% higher BMC or BMD values than normalweight subjects. Furthermore, in premenopausal women, there is a trend towards a more powerful relationship between lean body mass and bone variables, whereas in postmenopausal women the most powerful relationship is found between fat mass and bone variables. 29, 32 Also, some studies have found signi®cant relationships between bone mass and body weight, BMI or fat mass in women but not in men. 5, 29, 31 The pathophysiology behind the higher bone mass and density in obesity is unknown, but several mechanisms may be active. The increased`loading' or`strain' on the skeleton may have a positive in¯uence in net bone formation in the bone remodeling process. 11 In postmenopausal women the aromatization of androstendion to estrone (a well known bone preserving hormone) in the fat tissue may be a partial explanation. Finally, an increased PTH-level has been found in obese subjects, and this slightly increased PTH-level may have an anabolic effect on bone. 10 In most longitudinal studies performed, signi®cant effects have been found of weight loss on BMC or BMD. In a number of older studies in obese patients in whom intestinal by-pass or ventricular stapling operations were performed, there were decreases in BMC or BMD ranging from 2 to 10% after a considerable (20 ± 40 kg) weight loss. 3, 4 In intestinal bypass patients malabsorption of vitamin D and calcium may partly have in¯uenced bone metabolism. 3, 4, 15, 16, 33 A number of recent studies on diet-induced weight loss have found a signi®cant decline in bone mass values ranging from 1 ± 13%, partly dependent on the magnitude of the weight loss (3 ± 22 kg), the duration of the study (10 weeks to 12 months), the composition of diet, the region for determination of bone mass, and determination of either BMC or BMD. 8,9,34 ± 38 The loss in bone mass variables in the placebo group of the present study ranged from no change in TBMC, TBMD, lumbar spine BMC and lumbar spine BMD to 2.3 and 2.0% in forearm BMC and BMD, respectively. This was perfectly in accordance with the literature, however, contributing to a concept of a relatively modest bone loss with weight loss of only approximately 8 kg.
This is a substudy of a larger OLS study involving 688 patients receiving OLS or placebo.
1 After 1 y the 284 patients in the main study who completed OLS treatment had lost 10.3 vs 6.1 kg lost by the 260 patients who completed 1 y of placebo treatment. In our substudy the corresponding losses were 11.2 and 8.1 kg respectively, ie a lesser difference between OLS and placebo. It is possible that more signi®cant differences would had been seen if bone mass and calcium metabolic variables had been measured in the whole population.
It should be noted, that elevated parathyroid hormone levels in the context of obesity and obesity treatment may have at least three causes. First, a secondary hyperparathyroidism may be seen in morbid obesity due to change of behavioral pattern leading to decreased exposure to sunlight, and maybe a change in diet in favor of less vitamin D and calcium containing foods. 13, 39 Second, obesity in itself may in some unknown way induce a slight overproduction of Figure 1 Ratio of fasting urinary hydroxyproline to creatinine (mmola mmol) at baseline and after 1 y in 14 obese patients treated with orlistat (OLS) and the 16 obese patients given placebo. There were signi®cant increases in both the OLS (P`0.001) and in the placebo group (P`0.05); and a signi®cantly greater increase in the OLS group compared to the placebo group (P`0.05). OLS orlistat.
Orlistat, bones and body composition A Gotfredsen et al PTH, which may partly act to increase bone formation thereby contributing to the increase in bone mass seen in obesity. 10 Third, the treatment, such as in this case OLS, may induce a vitamin D and calcium de®cit and thereby a secondary hyperparathyroidism.
The ®nal confounding aspect in this rather complex matter is the question of the validity of DXA to measure BMC and BMD in obesity and changes in these variables during weight loss. DXA has a well known, and extensively investigated, inborn tendency to erroneous measurements of BMC and BMD due to very thick or very thin layers of soft tissue covering the bones. This`error' depends on rather simple radiophysical relationships, and it can therefore be predicted and corrected by theoretical or empirical computer algorithms and mechanicalatechnical ®ltering procedures. The problem is, however, that the correction procedures have been shown to have shortcommings due to the very wide variability and non-predictability of body soft tissue thicknesses and compositions. Therefore, even with the most sophisticated corrections, errors may be seen, resulting in over-or underestimation of BMC, bone area and BMD, and maybe even occational overcorrection of the errors. 17,18,40 ± 43 Furthermore, the different brands of DXA-scanners use quite different correction procedures which make comparisons between them a rather delicate matter. 17, 18, 40 The typical direction of the errors are such that the BMC (and maybe, but not always BMD) may be overestimated in extreme obesity and underestimated in extreme thinness. Therefore also the decrease in BMC andaor BMD during weight loss may be overestimated. Irregularities in the fat deposition (ie over bone vs next to bone) may also cause errors, and the direction and magnitude of the errors may vary between scanner brands, types and software versions. Furthermore, estimation of the fat percentage may also be in¯uenced by errors (typically an overestimation of the fat percentage in extreme obesity), whereas the DXA-estimate of the total soft tisssue mass is always very accurate. The bottom line is that studies of the errors of accuracy of DXA must be performed with the same DXA-scanner brand, type and software as the clinical study in question.
There were in the present study small, non-signi®cant differences between the weights measured by scales and estimated by DXA (Table 2; 1.1 ± 1.4 kg differences). These differences are most likely to be explained by the precision error of the DXA weight estimate, which is approximately 2%. 20 We have made extensive studies on the accuracy errors of the Norland XR 36 also used in this study, 19 and using phantom measurements and measurements of large thicknesses of lard and ox muscle placed on the abdomen and thighs of healthy subjects, and found this apparatus to be very accurate for both BMC, BMD and fat percentage. In particular, we did not ®nd any signi®cant dependence on the total body BMC or BMD of changing the thickness and composition of these tissue materials. We therefore feel con®dent that the results we reached in the present study as to BMC, BMD and soft tissue composition values are valid.
We note that the body compositional changes largely corresponded between DXA and the TBK method. In both groups, and with both methods, the weight loss was approximately 10 kg, of which approximately 80% was fat lost, resuIting in a decrease of approximately 5% in the FM%.
In conclusion, 1 y of treatment with OLS induces a lipid malabsorption which enhances a dietary weight loss without any signi®cant deleterious effects on body composition. OLS induces a relative increase in bone turnover in favor of resorption, possibly due to malabsorption of vitamin D andaor calcium. However, no changes in bone mass or density are seen after 1 y of OLS treatment apart from those explained from the weight loss itself. Thus a one year OLS treatment seems safe from a`bone preserving' point of view. A vitamin D and calcium supplement should be taken during the treatment.
